Exciting Investor Call from Lucid Diagnostics
Lucid Diagnostics Inc. is gearing up for a significant conference call scheduled for Monday, September 8, 2025, at 8:30 AM ET. During this call, the company will discuss important insights from the recent Contractor Advisory Committee (CAC) meeting held on September 4. This call presents a valuable opportunity for investors to understand the latest developments in the ongoing efforts of Lucid Diagnostics in the field of cancer prevention.
Webcast and Participation Details
Participants can access the conference call conveniently via a webcast link that will be available in the investor relations section of Lucid Diagnostics' website. For those interested in joining through a phone call, U.S.-based callers can dial 1-800-836-8184, while international listeners should use 1-646-357-8785. When prompted, all participants should mention the conference call name "Lucid Diagnostics Investor Call" to connect seamlessly.
About the Conference Call Agenda
During this crucial call, Lucid Diagnostics will outline the discussions from the CAC meeting, focusing on the reconsideration of Local Coverage Determination (LCD) L39256 regarding its revolutionary EsoGuard Esophageal DNA Test. This test aims to detect upper gastrointestinal metaplasia, dysplasia, and neoplasia, focusing on patients at risk of esophageal cancer.
What is EsoGuard?
Lucid's EsoGuard test is at the forefront of preventing esophageal cancer. This innovative test is performed using samples collected through a noninvasive procedure, which enhances patient comfort while ensuring effective screening for esophageal precancer. The test, which utilizes the EsoCheck Esophageal Cell Collection Device, is the first of its kind aimed specifically at early detection, addressing the needs of the millions suffering from gastroesophageal reflux disease (GERD).
About Lucid Diagnostics Inc.
Lucid Diagnostics Inc., a commercial-stage cancer prevention medical diagnostics company, operates as a subsidiary of PAVmed Inc. The company is committed to addressing the pressing healthcare challenge posed by esophageal cancer, which affects a significant portion of the population. Lucid aims to provide solutions for patients who may be at risk due to chronic heartburn and other related conditions.
Investment Insights
Investors and stakeholders should pay close attention during the upcoming call, as it will cover essential topics such as operational updates, product developments, and strategic directions intended to enhance the company’s position in the cancer diagnostics market. By capitalizing on the growing awareness around cancer prevention and early detection, Lucid is poised to make a meaningful impact in the healthcare arena.
What to Expect After the Call
Following the conference call, a replay will be accessible for 90 days through the investor relations website of Lucid Diagnostics, allowing interested parties to catch up on the critical updates shared during the discussion.
Frequently Asked Questions
What is the date and time of the investor call?
The investor call is scheduled for Monday, September 8, 2025, at 8:30 AM ET.
How can I participate in the investor call?
You can join the call via the provided webcast link or by calling the designated U.S. or international phone numbers.
What will be discussed during the investor call?
The call will focus on the discussions from the recent CAC meeting regarding Lucid’s EsoGuard test and other vital company updates.
Who should participate in this call?
This call is suitable for investors, stakeholders, and anyone interested in the developments at Lucid Diagnostics.
How long will the replay of the call be available?
The replay will be available for 90 days on the investor relations page of Lucid Diagnostics’ website.
